AC Immune SA balance sheet

At the end of fiscal 2025, AC Immune SA had total assets of $194m, total liabilities of $138m and shareholders' equity of $56.6m. It held $33.8m in cash against $0 of debt: net cash of $33.8m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

AC Immune SA: balance sheet, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	76	150	128	159	200	182	90	34	93	40	34
Total current assets	—	152	133	196	303	262	222	139	149	190	122
Total assets	—	154	136	200	309	270	286	201	218	255	194
Total current liabilities	—	10	10	13	18	16	22	12	16	111	119
Total debt	0	0	0	0	0	0	0	0	0	0	0
Total liabilities	—	14	16	19	28	26	32	18	26	131	138
Shareholders' equity	71	140	120	181	282	244	254	183	191	124	57
Net debt (negative = net cash)	−76	−150	−128	−159	−200	−182	−90	−34	−93	−40	−34

US$ millions unless shown otherwise. Fiscal quarters.

AC Immune SA: balance sheet, quarterly
Quarter	2017 Q1Mar 2017	2017 Q2Jun 2017	2017 Q3Sept 2017	2017 Q4Dec 2017	2018 Q1Mar 2018	2018 Q2Jun 2018	2018 Q3Sept 2018	2018 Q4Dec 2018
Total current assets	—	—	—	133	—	—	—	196
Total assets	—	—	—	136	—	—	—	200
Total current liabilities	—	—	—	10	—	—	—	13
Total liabilities	—	—	—	16	—	—	—	19
Shareholders' equity	—	—	—	120	—	—	—	181

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ACIU vs CRIS ACIU vs CAMP ACIU vs ENSC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from AC Immune SA's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to AC Immune SA.